Brief: Annexon Reports First Quarter 2023 Financial Results

Annexon

08/05/2023 23:16

May 8 (Reuters) - Annexon Inc  ANNX.O :
    * ANNEXON REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND
HIGHLIGHTS RECENT PIPELINE PROGRESS
    * ANNEXON- STRONG FINANCIAL POSITION WITH OPERATING RUNWAY
INTO
2025, WITH MULTIPLE MID-STAGE & PIVOTAL CLINICAL TRIAL READOUTS
EXPECTED ACROSS 2023,2024
    * ANNEXON - ENROLLMENT EXPECTED TO BE COMPLETED IN PHASE 3
TRIAL
IN GUILLAIN-BARRÉ SYNDROME DURING 2H'23, WITH INITIAL TOPLINE
RESULTS EXPECTED IN 1H'24
    * INITIAL CLINICAL DATA ANTICIPATED FROM PHASE 1B TRIAL OF
ANX009
IN LUPUS NEPHRITIS IN 1H'23
    * INITIAL CLINICAL DATA EXPECTED FROM PHASE 2 ARCHER TRIAL
OF
ANX007 IN GEOGRAPHIC ATROPHY IN MID-2023
    * CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE
$228.2
MILLION AS OF MARCH 31, 2023
    * QTRLY LOSS PER SHARE $0.52
    * Q2 EARNINGS PER SHARE VIEW $-0.53 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX3JhdBV 
Further company coverage:  ANNX.O 

 ((Reutersbriefs@thomsonreuters.com;))